Barclays PLC reduced its position in shares of Surgery Partners, Inc. (NASDAQ:SGRY – Free Report) by 62.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 129,133 shares of the company’s stock after selling 211,901 shares during the period. Barclays PLC owned 0.10% of Surgery Partners worth $4,164,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of SGRY. KBC Group NV grew its holdings in Surgery Partners by 31.8% in the third quarter. KBC Group NV now owns 2,385 shares of the company’s stock worth $77,000 after purchasing an additional 576 shares during the period. Quarry LP boosted its position in Surgery Partners by 133.1% in the second quarter. Quarry LP now owns 3,082 shares of the company’s stock worth $73,000 after purchasing an additional 1,760 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its position in Surgery Partners by 747.6% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,831 shares of the company’s stock valued at $124,000 after buying an additional 3,379 shares during the period. Creative Planning bought a new position in Surgery Partners in the 3rd quarter worth $258,000. Finally, Versor Investments LP bought a new position in shares of Surgery Partners in the third quarter worth about $271,000.
Surgery Partners Trading Up 8.2 %
Shares of SGRY stock opened at $21.22 on Monday. The stock’s fifty day moving average is $25.99 and its two-hundred day moving average is $27.77. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.66 and a current ratio of 1.80. The firm has a market capitalization of $2.70 billion, a P/E ratio of -44.21, a PEG ratio of 17.40 and a beta of 2.58. Surgery Partners, Inc. has a fifty-two week low of $19.50 and a fifty-two week high of $35.29.
Wall Street Analyst Weigh In
SGRY has been the subject of several research analyst reports. Bank of America began coverage on Surgery Partners in a research report on Monday, December 16th. They set a “buy” rating and a $30.00 target price for the company. Benchmark reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Surgery Partners in a research note on Monday, August 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $43.00 target price on shares of Surgery Partners in a research note on Friday, October 4th. UBS Group started coverage on Surgery Partners in a research note on Monday, October 14th. They set a “buy” rating and a $38.00 price target for the company. Finally, JPMorgan Chase & Co. decreased their price target on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.56.
Get Our Latest Research Report on Surgery Partners
About Surgery Partners
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Featured Articles
- Five stocks we like better than Surgery Partners
- Canada Bond Market Holiday: How to Invest and Trade
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- Russell 2000 Index, How Investors Use it For Profitable Trading
- CarMax Gets in Gear: Is Now the Time to Buy?
- What is the Australian Securities Exchange (ASX)
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.